TxBench-PP: Analyzing AI Agent Performance on Small-Molecule Preclinical Pharmacology
arXiv AIArchived Jun 18, 2026✓ Full text saved
arXiv:2606.19245v1 Announce Type: new Abstract: Artificial intelligence (AI) agents promise to accelerate drug discovery by compressing interpretation and decision-making loops, but practical deployment requires trusted evaluation on realistic program decisions. We introduce TherapeuticsBench Preclinical Pharmacology (TxBench-PP), a verifiable benchmark for small-molecule preclinical pharmacology and the first focused slice of a broader TherapeuticsBench effort across drug-discovery stages and t
Full text archived locally
✦ AI Summary· Claude Sonnet
Computer Science > Artificial Intelligence
[Submitted on 17 Jun 2026]
TxBench-PP: Analyzing AI Agent Performance on Small-Molecule Preclinical Pharmacology
Hannah Le, Ramesh Ramasamy, Alex Urrutia, Mahsa Yazdani, Tim Proctor, Kenny Workman
Artificial intelligence (AI) agents promise to accelerate drug discovery by compressing interpretation and decision-making loops, but practical deployment requires trusted evaluation on realistic program decisions. We introduce TherapeuticsBench Preclinical Pharmacology (TxBench-PP), a verifiable benchmark for small-molecule preclinical pharmacology and the first focused slice of a broader TherapeuticsBench effort across drug-discovery stages and therapeutic modalities. TxBench-PP tests whether agents can recover accurate conclusions from real-world assay data rather than memorized facts from literature. The benchmark contains 100 evaluations indexed by program stage, assay type, and task structure, spanning mechanism-of-action (MoA) and pharmacodynamic (PD) reasoning, compound-target engagement, causal target validation, developability and safety, and translational efficacy. Agents receive realistic workflow snapshots, inspect files in a coding environment, and return structured answers graded deterministically. Across 16 model-harness configurations, comprising 11 models and 4,800 trajectories, no system reliably recovered preclinical pharmacology decisions. The strongest configuration, Claude Opus 4.8 / Pi, passed 59.3\% of endpoint attempts (178/300; 95\% CI, 51.1-67.6), followed by GPT-5.5 / Pi at 55.3\% (166/300; 47.0-63.6).
Subjects: Artificial Intelligence (cs.AI); Machine Learning (cs.LG)
Cite as: arXiv:2606.19245 [cs.AI]
(or arXiv:2606.19245v1 [cs.AI] for this version)
https://doi.org/10.48550/arXiv.2606.19245
Focus to learn more
Submission history
From: Kenny Workman B [view email]
[v1] Wed, 17 Jun 2026 16:23:45 UTC (264 KB)
Access Paper:
HTML (experimental)
view license
Current browse context:
cs.AI
< prev | next >
new | recent | 2026-06
Change to browse by:
cs
cs.LG
References & Citations
NASA ADS
Google Scholar
Semantic Scholar
Export BibTeX Citation
Bookmark
Bibliographic Tools
Bibliographic and Citation Tools
Bibliographic Explorer Toggle
Bibliographic Explorer (What is the Explorer?)
Connected Papers Toggle
Connected Papers (What is Connected Papers?)
Litmaps Toggle
Litmaps (What is Litmaps?)
scite.ai Toggle
scite Smart Citations (What are Smart Citations?)
Code, Data, Media
Demos
Related Papers
About arXivLabs
Which authors of this paper are endorsers? | Disable MathJax (What is MathJax?)